{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=40",
    "query": {
      "condition": "Neuroectodermal Tumor",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 5015,
    "total_pages": 502,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T16:49:55.882Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04598009",
      "title": "Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma Stage III",
        "Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-03-03",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • San Francisco, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04598009"
    },
    {
      "nct_id": "NCT03776071",
      "title": "A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Enzastaurin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Denovo Biopharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2020-12-16",
      "completion_date": "2024-02-29",
      "has_results": false,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03776071"
    },
    {
      "nct_id": "NCT05864144",
      "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Advanced Solid Tumor",
        "Head and Neck Cancer",
        "Breast Cancer",
        "Colon Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Prostate Cancer",
        "Uterine Cancer",
        "Cervix Cancer",
        "Ovarian Cancer",
        "Kidney Cancer",
        "Bladder Cancer",
        "Thyroid Cancer",
        "Melanoma",
        "Sarcoma",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Refractory Cancer",
        "Non Small Cell Lung Cancer",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "SNS-101 (anti-VISTA)",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sensei Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2023-05-31",
      "completion_date": "2026-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05864144"
    },
    {
      "nct_id": "NCT06627244",
      "title": "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Uveal Melanoma",
        "Metastatic Uveal Melanoma in the Liver"
      ],
      "interventions": [
        {
          "name": "Tebentafusp",
          "type": "DRUG"
        },
        {
          "name": "TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-02-14",
      "completion_date": "2031-02-17",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06627244"
    },
    {
      "nct_id": "NCT05060432",
      "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "EOS-448",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "inupadenant",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "SOC chemotherapies",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "iTeos Belgium SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2021-09-06",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Bergen, New Jersey",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bergen",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05060432"
    },
    {
      "nct_id": "NCT00629187",
      "title": "Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Central Nervous System Neoplasms",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2,
      "start_date": "2004-04",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2012-04-27",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00629187"
    },
    {
      "nct_id": "NCT05835687",
      "title": "Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Central Nervous System Neoplasms",
        "Atypical Teratoid/Rhabdoid Tumor",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Ependymoma",
        "High Grade Glioma",
        "Glioblastoma",
        "Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "B7-H3-CAR T cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 29,
      "start_date": "2023-04-27",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05835687"
    },
    {
      "nct_id": "NCT02355587",
      "title": "Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cutaneous Melanoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Castle Biosciences Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2014-03",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-10-08",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 4,
      "location_summary": "Santa Rosa, California • Frederick, Maryland • Las Vegas, Nevada + 1 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Frederick",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02355587"
    },
    {
      "nct_id": "NCT02315534",
      "title": "A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "BBI608",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2015-03",
      "completion_date": "2019-06-24",
      "has_results": true,
      "last_update_posted_date": "2023-11-15",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315534"
    },
    {
      "nct_id": "NCT00780663",
      "title": "Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Carcinoid Tumor"
      ],
      "interventions": [
        {
          "name": "Quarfloxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cylene Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2008-10",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2011-06-15",
      "last_synced_at": "2026-10-28T16:49:55.882Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Fort Collins, Colorado + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Las Cruces",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00780663"
    }
  ]
}